Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338821 | 0.84 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL5067478 | 0.84 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL7691543 | 0.81 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL13980023 | 0.81 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL10358866 | 0.81 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL3051865 | 0.80 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL14821250 | 0.79 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL31037188 | 0.79 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL14154795 | 0.79 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL29256447 | 0.79 | MAPK1 (0.50) | NPC1RAB9ASMN1; SMN2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063205-B2 | Method for producing 2-oxazoline analogue or 1,3-oxazine analogue | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1956012-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | National University Corporation Hokkaido University (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | OXA1L, SULT1A1, DAO | NPC1 4531/4885RAB9A 3802/4885SMN1; SMN2 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.